Patent ID: 11957660
Assignee: MITSUBISHI TANABE PHARMA CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. An edaravone suspension for human oral administration, comprising:
water;
a thickening agent comprising at least one of tragacanth powder and xanthan gum;
edaravone particles comprising edaravone and dispersed in the water; and
a dispersant dispersing the edaravone particles in the water such that the dispersant maintains the edaravone particles in a solid particle state in the water,
wherein a blending amount of the edaravone particles is in a range of 0.2% (w/v) to 36% (w/v), and the edaravone suspension does not contain a preservative selected from the group consisting of methylparaben, ethylparaben, propylparaben, butylparaben, benzoic acid, sorbic acid, sodium benzoate, benzyl alcohol, phenylethanol and a combination thereof, and does not have a bacterial growth for at least 28 days according to the preservation efficacy test of Japanese Pharmacopeia.